NIOX® develops and produces state-of-the-art technology for asthma diagnosis and management. Our aim is to improve the lives of people suffering from asthma by helping physicians assess patients more accurately. Our market-leading device, NIOX VERO®, measures the level of fractional exhaled nitric oxide (FeNO) in the breath, with results proven to help with asthma treatment.^1-3

NIOX® was the first to commercialise FeNO testing over 25 years ago. We’re proud to say NIOX® remains the gold standard device⁴, with more than 50 million tests performed worldwide and counting.

1. Carroll 2016. 2. Hanania 2018. 3. Price 2018. 4. Data on File; MKT-DOF-007. 2023.